Kura Oncology, Inc. expected to post a loss of 88 cents a share - Earnings Preview
Kura Oncology, Inc. <KURA.OQ> expected to post a loss of 88 cents a share - Earnings Preview
Kura Oncology, Inc. KURA.OQ KURA.O is expected to show a rise in quarterly revenue when it reports results on August 12 for the period ending June 30 2026
The San Diego California-based company is expected to report a 40.1% increase in revenue to $21.42 million from $15.29 million a year ago, according to the mean estimate from 14 analysts, based on LSEG data.
LSEG's mean analyst estimate for Kura Oncology, Inc. is for a loss of 88 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Kura Oncology, Inc. is $28.00, about 192.6% above its last closing price of $9.57
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2026 | -0.62 | -0.63 | -0.83 | Missed | -31.1 |
Dec. 31 2026 | -0.54 | -0.48 | -0.92 | Missed | -89.7 |
Sep. 30 2025 | -0.89 | -0.85 | -0.85 | Met | 0.2 |
Jun. 30 2025 | -0.48 | -0.46 | -0.75 | Missed | -63.4 |
Mar. 31 2025 | -0.45 | -0.39 | -0.66 | Missed | -68.9 |
Dec. 31 2024 | -0.63 | -0.64 | -0.22 | Beat | 65.5 |
Sep. 30 2024 | -0.61 | -0.63 | -0.63 | Met | -0.7 |
Jun. 30 2024 | -0.62 | -0.63 | -0.59 | Beat | 6.2 |
This summary was machine generated August 10 at 20:30 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)